Effects of Del Nido and Terminal Warm Blood Cardioplegia on Myocardial Protection and Rhythm in Isolated CABG Patients
Keywords:del Nido cardioplegia, Coronary artery bypass grafting, Myocardial protection, Fibrilation
Objective: To investigate the effect of using del Nido cardioplegia+terminal hot-shot blood cardioplegia on myocardial protection and rhythm in isolated coronary bypass patients.
Material and methods: A total of 122 patients were given cold (+4-8C') del Nido cardioplegia antegrade and evaluated. Del Nido+terminal warm blood cardioplegia (TWBCP) was applied to 63 patients out of 122 patients, while del Nido cardioplegia alone was applied to the other 59 patients. The preoperative and postoperative data of the patients were recorded and compared.
Results: There was a significant statistical difference between the groups, in terms of volume with more cardioplegia in the del Nido+terminal warm blood cardioplegia group. Although there was no significant difference between cardiac arrest times in both groups, a statistically significant difference was found in the del Nido+terminal warm blood cardioplegia group in the starting to work time of the heart. No difference found between the groups regarding myocardial preservation.
Conclusions: We can add a return to spontaneous sinus rhythm to the advantages of terminal warm blood cardioplegia and del Nido cardioplegia in literature. We think it would be a good strategy to extend the safe ischemic time limit of del Nido to 120 minutes with a terminal warm blood cardioplegia. It seems that cardioplegia techniques that will be developed by adding the successful and superior results of crystalloid cardioplegia applications, such as single dose del Nido in various open heart surgery operations and the superior myocardial return effects of terminal warm blood cardioplegia, will be used routinely in the future.
Ad N, Holmes SD, Massimiano PS, et al. 2018. The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial J Thorac Cardiovasc Surg. 155:1011-1018.
Bigelow WG, Lindsay WK, Greenwood WF. 1950. Hypothermia; its possible role in cardiac surgery: an investigation of factors governing survival in dogs at low body temperatures. Ann Surg. 132:849-866.
Buckberg GD, Athanasuleas CL. 2016. Cardioplegia: solution or strategies? Eur J Cardiothorac Surg. 50:787-791.
Cagdas C, M, Yuksel A. 2020. The Use of del Nido Cardioplegia for Myocardial Protection in Isolated Coronary Artery Bypass Surgery. Heart Lung Circ. 29:301-307.
Caputo M, Dihmis WC, Bryan AJ, et al. 1998. Warm blood byperkalemic reperfusion (’hot shot’) prevents myocardial substrate derangement in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg. 13:559-564.
Govindapillai A, Hua R, Rose R, et al. 2013. Protecting the aged heart during cardiac surgery: use of del Nido cardioplegia provides superior functional recovery in isolated hearts. J Thorac Cardiovasc Surg. 146:940-948.
Hamad R, Nguyen A, Laliberte´ E´, et al. 2017. Comparison of del Nido cardioplegia with blood cardioplegia in adult combined surgery. Innovations (Phila). 12:356-362.
Kim K, Ball C, Grady P, et al. 2014. Use of del Nido Cardioplegia for Adult Cardiac Surgery at the Cleveland Clinic: Perfusion Implications. J Extra Corpor Technol. 46:317-323.
Li Y, Lin H, Zhao Y, et al. 2018. Del Nido cardioplegia for myocardial protection in adult cardiac surgery: a systematic review and meta-analysis. ASAIO J. 64:360-367.
Matte GS, del Nido PJ. 2012. History and use of del Nido cardioplegia solution at Boston Children’s Hospital. J Extra Corpor Technol. 44:98-103.
Melrose DG, Dieger DB, Bentall HH, et al. 1955. Elective cardiac arrest. Lancet. 269:21-22.
Nakao M, Morita K, Shinohara G, et al. 2020. Superior restoration of left ventricular performance after prolonged single-dose del Nido cardioplegia in conjunction with terminal warm blood cardioplegic reperfusion. J Thorac Cardiovasc Surg. 5223:33300-33306.
O’Blenes SB, Friesen CH, Ali A, et al. 2011. Protecting the aged heart during cardiac surgery: The potential benefits of del Nido cardioplegia. J Thorac Cardiovasc Surg. 141:762-770.
O’Brien JD, Howlett SE, Burton HJ, et al. 2009. Pediatric cardioplegia strategy results in enhanced calcium metabolism and lower serum troponin T. Ann Thorac Surg. 87:1517-1523.
Pieri M, Belletti A, Monaco F, et al. 2016. Outcome of cardiac surgery in patients with low preoperative ejection fraction. BMC Anesthesiol. 16:97.
Ramanathan R, Parrish DW, Armour TK, et al. 2015. Use of del Nido cardioplegia in adult cardiac surgery. Thorac Cardiovasc Surg. 63:624-627.
Ristagno G, Wang T, Tang W, et al. 2008. High-energy defibrillation impairs myocyte contractility and intracellular calcium dynamics. Crit Care Med. 36:422-427.
Schutz A, Zhang Q, Bertapelle K, et al. 2020. Del Nido cardioplegia in coronary surgery: a propensity-matched analysis. Interact Cardiovasc Thorac Surg. May;30:699-705.
Scott T, Swanevelder J. 2009. Perioperative myocardial protection. Continuing Education in Anaesthesia Critical Care & Pain. 9: 97–101.
Siddiqi S, Blackstone EH, Bakaeen FG. 2018. Bretschneider and del Nido solutions: Are they safe for coronary artery bypass grafting? If so, how should we use them? J Card Surg 33:229-234.
Teoh KH, Christakis GT, Weisel RD, et al. 1986. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia. J Thorac Cardiovasc Surg. 91:888-895.
Timek T, Willekes C, Hulme O, et al. 2016. Propensity matched analysis of del Nido cardioplegia in adult coronary artery bypass grafting: initial experience with 100 consecutive patients. Ann Thorac Surg. 101:2237-2241.
Volpi S, Ali JM, De Silva R. 2019. Does the use of a hot-shot lead to improved outcomes following adult cardiac surgery? Interact Cardiovasc Thorac Surg. 28:473-477.
Yerebakan H, Sorabella RA, Najjar M, et al. 2014. Del Nido Cardioplegia can be safely administered in high-risk coronary artery bypass grafting surgery after acute myocardial infarction: a propensity matched comparison. J Cardiothorac Surg. 30:141.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).